Diagnosis
Herpes zoster
Reactivation of the varicella-zoster virus characterized by a painful skin rash with blisters in a limited area on one side of the body.
Also known as: Shingles, Zoster
Etiology
Cause
Varicella-zoster virus (reactivation)
Patophysiology [3ug][y5q]
Varicella (chickenpox) is the initial self-limited varicella zoster virus infection
The virus remains dormant within dorsal root ganglia without causing any symptoms
Decades after the initial infection, the virus may reactivate and travel down nerve axons to cause herpes zoster (shingles)
Painful skin rash with blisters limited to the corresponding dermatome
Triggers for herpes zoster:
Emotional stress
Use of immunosuppressants
Acute or chronic illness
Exposure to the virus
Presence of a malignancy
Preeruptive stage (48 hours prior to rash): abnormal skin sensations or pain within the dermatome affected, headaches, general malaise, and photophobia
The acute eruptive phase (2-4 weeks): macules quickly transform into painful vesicles which rupture, ulcerate and eventually crust (most infectious and severe pain)
Chronic infection (>12 months): recurrent pain, paresthesias, shock-like sensations, and dysesthesias.
Risk factors
Immunosuppression
Cancer
Age
Complications
Postherpetic neuralgia
Secondary bacterial infection
Cranial neuropathies
Shingles oticus (Ramsay Hunt syndrome type II): hearing loss and vertigo
Polyneuritis
Myelitis
Meningitis
Encephalitis
Guillain-Barre syndrome
Herpes Zoster Ophthalmicus/keratitis
Epidemiology
Incidence per 100.000 [gut][zsu][crz][5zm][qre]
Symptoms & findings
Symptoms
Anopsia, Anorexia, Confusion, Dysuria, Facial nerve paralysis, Fatigue, Fever, Headache, Hearing loss, Hematuria, Hyperesthesia, Lymphadenopathy, Malaise, Myalgia, Nausea, Neck stiffness, Otalgia, Paralysis, Paresis, Paresthesia, Photophobia, Tinnitus, Vertigo, Vomiting
Clinical findings
None listed.
Anamneses
None listed.
Localized findings
Approach
Blood test
Tsanck smear
PCR from blister
Lumbar puncture
Ophthalmoscopy
Treatment
Generally self-limited and resolve without intervention. Herpes zoster infection tend to be more benign and mild in children than in adults. Therapy might reduce the extent and duration of symptoms, and possibly the risk of chronic sequelae [3ug]:
Prevention: Varicella-zoster virus vaccine
Supportive care:
Wet dressing with 5% aluminum acetate (Burow solution) for 1 hour 5 times/day
Lotions (calamine)
Medications:
Analgesics/anti-inflammatory:
NSAIDs
Steroids
Topical lidocaine and capsaicin
Anticonvulsant agents (gabapentin)
Antiviral agents [y5q]
Topical acyclovir 5% cream
Systemic acyclovir and its derivatives (valacyclovir and famciclovir)
Acyclovir 800 mg five times daily for 5 days
Valacyclovir 1 gram three times daily for 5 days
Admission to hospital if:
Severe symptoms
Immunosuppression
Atypical presentations (eg, myelitis)
Involvement of more than 2 dermatomes
Significant facial bacterial superinfection
Disseminated herpes zoster
Ophthalmic involvement
Meningoencephalopathic involvement
Differential diagnoses
Acneiform eruptions, Acne keloidalis nuchae, Acute poliomyelitis, Angina pectoris, Aphthous stomatitis, Appendicitis, Bell's Palsy, Brain tumor, Candidiasis, Cellulitis, Chickenpox, Cholecystitis, Cholelithiasis, Conjunctivitis, Contact dermatitis, Cowpox infection, Coxsackievirus infection, Dental infection, Ecthyma, Eczema, Encephalitis, Erysipelas, Erysipeloid, Folliculitis, Furunculosis, Glaucoma, Herpangina, Herpes simplex, Insect Bite, Iridocyclitis, Jellyfish stings, Keratitis, Lichen striatus, Lyme disease, Lymphangioma circumscriptum, Measles, Meniere disease, Meningitis, Multiple sclerosis, Myasthenia gravis, Optic neuritis, Retinitis, Spinal disc herniation, Spinal stenosis, Stroke, Superficial pyoderma, Syphilis, Trigeminal neuralgia, Urinary tract infection, Urolithiasis, Uveitis, Vestibular neuronitis
References
[1] http://emedicine.medscape.com/article/1132465 (2014-01-02); [Medscape]
[2] Nair PA, Patel BC. Herpes Zoster. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441824/
[3] Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995 Aug 7-21;155(15):1605-9.
[4] van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010 Aug 13;10:237.
[5] MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One. 2015 Apr 30;10(4):e0125025.
[6] Mirinaviciute G, Quist-Paulsen E, Brantsæter AB, Flem E. The burden of herpes zoster disease in Norway. Vaccine. 2020 Apr 16;38(18):3501-3507.
[7] Pérez-Farinós N, Ordobás M, García-Fernández C, García-Comas L, Cañellas S, Rodero I, Gutiérrez-Rodríguez A, García-Gutiérrez J, Ramírez R. Varicella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997-2004. BMC Infect Dis. 2007 Jun 15;7:59.